Pulmatrix (NASDAQ:PULM) Shares Pass Below 50 Day Moving Average – Here’s Why

by · The Markets Daily

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.47 and traded as low as $2.36. Pulmatrix shares last traded at $2.36, with a volume of 33,436 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a research note on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

View Our Latest Report on PULM

Pulmatrix Stock Down 1.5%

The business’s fifty day moving average price is $4.42 and its 200 day moving average price is $5.24.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Thursday, October 16th. The biotechnology company reported ($0.24) earnings per share for the quarter.

Institutional Trading of Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP purchased a new position in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix as of its most recent SEC filing. 11.84% of the stock is owned by institutional investors and hedge funds.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).

See Also